RETRACTION

Open Access Full Text Article

## MicroRNA-211 Promotes Non-Small-Cell Lung Cancer Proliferation and Invasion by Targeting MxA [Retraction]

Kang M, Shi J, Peng N, He S. Onco Targets Ther. 2017;10:5667-5675.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 2D and 5C. Specifically,

• Figure 2D, A549, Negative control appears to have been duplicated with the same image for Figure 5C, H1650, MxA-specific siRNA.

The authors did not respond to our queries and no explanation for the alleged image duplication was provided. The Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

## **OncoTargets and Therapy**

Dovepress

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S397678

Received: 15 November 2022 Accepted: 15 November 2022 Published: 16 November 2022

## OncoTargets and Therapy 2022:15 1387

1387

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Greative Commons Attribution – Non Commercial (unported, v3.0). License (http://creativecommons.org/licenses/by-n/3.0). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for ownedical press Limited, provided the work is properly attributed. For permission for commercial use of the work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).